% | $
Quotes you view appear here for quick access.

Verastem, Inc. (VSTM) Message Board

  • iwannapancake iwannapancake Jun 26, 2013 9:57 AM Flag

    Things are happening very quickly now at Verastem

    “It is exciting to bring a novel small molecule inhibitor targeting the FAK pathway, a key regulator of cancer stem cells, into the clinic,” said Principal Investigator Alain Mita, M.D., Co-Director, Experimental Therapeutics Program, Cedars-Sinai Medical Center, Los Angeles, CA. “There is significant scientific evidence to suggest that FAK could be an important therapeutic target in metastatic solid tumors. We have incorporated a biomarker strategy into the design of this trial to help us further define the role of cancer stem cells and FAK in disease progression for patients with advanced tumors.”

    “We believe that cancer stem cells are ultimately responsible for disease progression in many cancers,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “By inhibiting FAK, we have the potential to directly address this underlying cell population in tumors. This study should give us the necessary safety profile and dosing information to determine the future course of clinical development for VS-4718.”

    Sentiment: Strong Buy

1.31-0.03(-2.24%)Jun 24 4:00 PMEDT